• HyperScribe T7 High Yield RNA Synthesis Kit: Advanced Applic

  2026-07-06

  The HyperScribe™ T7 High Yield RNA Synthesis Kit accelerates high-yield, high-fidelity in vitro RNA synthesis for advanced research, from capped and biotinylated RNA production to mRNA therapeutics. Its robust protocol, combined with proven troubleshooting strategies and translational use-cases, empowers scientists to streamline workflows and improve experimental reproducibility.

• Tioconazole in Antifungal Drug Development: Protocols & Insi

  2026-07-06

  Tioconazole, a high-purity antifungal medication, empowers researchers to dissect ergosterol biosynthesis and resistance mechanisms with precision. Explore optimized protocols, advanced applications, and troubleshooting strategies leveraging APExBIO's trusted supply for reproducible antifungal research.

• Cholesterol Impedes Intracellular Trafficking of Lipid Nanop

  2026-07-05

  This study reveals that increasing cholesterol content in lipid nanoparticles (LNPs) leads to their aggregation in peripheral early endosomes, thereby hindering efficient intracellular trafficking and reducing nucleic acid cargo delivery. The findings guide future design and optimization of LNP-based delivery systems for nucleic acid therapeutics, highlighting the nuanced roles of lipid components.

• JSH-23: NF-κB Inhibitor-Driven Innovation in Inflammation Re

  2026-07-04

  JSH-23 stands out as a precise NF-κB inhibitor for dissecting inflammatory signaling and modeling cytokine-driven pathologies. This article delivers actionable workflows, troubleshooting strategies, and insights into leveraging JSH-23 for robust, reproducible results in both cellular and in vivo systems.

• Doxorubicin Hydrochloride: Optimizing Cancer and Cardiotoxic

  2026-07-03

  Doxorubicin hydrochloride (Adriamycin HCl) is a gold-standard agent for modeling cytotoxicity, apoptosis, and cardiotoxicity in translational oncology research. This article bridges cutting-edge mechanistic insights with actionable protocols, troubleshooting, and workflow enhancements, empowering researchers to maximize the value of APExBIO's Doxorubicin HCl across diverse cancer models.

• Aprotinin (BPTI): Strategic Protease Inhibition in Translati

  2026-07-03

  Explore how Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) is reshaping translational research with its mechanistic precision, impact on perioperative blood management, and role in advanced molecular profiling. This article bridges workflow optimization with strategic guidance, integrating latest protocol innovations and evidence-backed insights.

• T0070907: Precision PPARγ Antagonist for Pathway Dissection

  2026-07-02

  T0070907 enables researchers to dissect PPARγ-dependent signaling and cell fate decisions with nanomolar precision. Its unique mechanism as a covalent PPARγ antagonist makes it the tool of choice for advanced studies in adipogenesis inhibition, SASP inflammation, and cancer cell cycle regulation.

• Alpha-Ketoglutarate in Metabolic Reprogramming Workflows

  2026-07-02

  Alpha-ketoglutarate empowers precise dissection of mitochondrial metabolism, immune modulation, and chemotherapy response in advanced research. This guide bridges foundational TCA cycle principles with actionable protocols and troubleshooting strategies, making it indispensable for metabolic reprogramming studies.

• Deferiprone: Precision Iron Modulation in Translational Rese

  2026-07-01

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is a high-affinity iron chelator that has transformed the landscape of cancer biology and metabolic research by enabling precise, tunable control over iron-dependent cellular processes. This article synthesizes recent mechanistic insights—highlighting how iron stress reshapes enterocyte metabolism and cancer cell fate—with actionable protocol guidance for translational researchers. We contrast Deferiprone’s unique mechanistic and technical advantages with alternative approaches, emphasizing its position as the gold standard for apoptosis induction via iron depletion, protection against doxorubicin-induced cytotoxicity, and modeling of iron-mediated signaling in both tumor and neurovascular contexts.

• Efficient GRO-seq Protocol for Nascent RNA Profiling in Brea

  2026-07-01

  Chen et al. present a cost-effective GRO-seq protocol with rRNA removal, dramatically increasing valid nascent RNA data yield in bread wheat. This method enables high-resolution transcriptional profiling in complex plant genomes, with broad implications for genomic research efficiency.

• Luminescent ATP Detection Assay Kit: Precision in Energy Met

  2026-06-30

  The Luminescent ATP Detection Assay Kit from APExBIO delivers unmatched sensitivity and streamlined workflows for quantifying ATP in cells, tissues, and solutions. Its firefly luciferase chemistry and robust lysis buffer unlock reproducible, high-throughput energy metabolism assays across diverse research models.

• AT13387: Next-Generation Hsp90 Inhibitor in Cancer Biology R

  2026-06-30

  AT13387 sets a new standard for Hsp90 inhibition, enabling precise control of apoptosis and cell cycle arrest in cancer models. Its distinct structure, oral bioavailability, and robust tumor retention empower advanced experimental workflows and translational discovery.

• Technical Guide: HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-06-29

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for efficient, high-yield synthesis of randomly Cy3-labeled RNA probes, supporting sensitive fluorescent detection in workflows such as in situ hybridization and Northern blotting. This kit is intended solely for research use and is not suitable for diagnostic, clinical, or therapeutic applications.

• Microfluidic Peptide/RNA Complexes for Pulmonary mRNA Delive

  2026-06-29

  This article reviews a recent study demonstrating the use of microfluidic mixing to generate robust peptide/mRNA complexes suitable for nebulized pulmonary delivery. The findings highlight preservation of transfection efficiency after aerosolization, pointing to the clinical potential of non-viral peptide vectors for mRNA therapeutics targeting lung diseases.

• KN-62: Advanced Strategies for CaMKII-Targeted Calcium Signa

  2026-06-28

  Explore how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, enables precise inhibition of CaMKII and dissection of calcium signaling in metabolism and cell cycle control. This article provides nuanced guidance for experimental design, leveraging recent mechanistic insights and practical assay optimizations.

548 records 12/37 page Previous Next First page 上5页 1112131415 下5页 Last page